Clinical Trial: FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma

U.S., Jan. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07314372) titled 'FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma' on Nov. 22, 2025.

Brief Summary: This study is a prospective, multicenter Phase II trial evaluating a personalized treatment strategy for patients with unresectable hepatocellular carcinoma (HCC). The study uses a metabolic classification system called the fatty acid degradation (FAD) subtype to guide therapy selection. Patients will be assigned to different treatment groups based on their tumor's FAD subtype, determined through RNA-seq analysis of the tumor tissue obtained from liver biopsy.

Study Start Date: Feb. 01

Study Type: INTERVENTIONAL

Condi...